Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
-
EHE Resource Recap, October 2021
HHS has funded multiple agencies to deliver technical assistance and training to Ending the HIV Epid
News Article updated on 10/18/2021 -
Needs Assessment Tool Series: Focus Groups
-
HRSA Revises RWHAP Policy Notice on Eligibility Determinations
In October 2021, HRSA's HIV/AIDS Bureau revised its client eligibility and recertification policy for the Ryan White HIV/AIDS Program.
News Article updated on 11/02/2021 -
HRSA Releases New Fact Sheets on RWHAP Clients
Ten fact sheets on client populations getting care from the Ryan White HIV/AIDS Program (RWHAP) a
News Article updated on 06/30/2021 -
Online Course on Integrated Planning
-
RWHAP Program Letter: ADAPs and SUD Medications
On May 11, HRSA’s HIV/AIDS Bureau released a program letter encouraging RWHAP ADAP recipients to include medications for SUDs, including buprenorphine for OUD, and naloxone for opioid overdose prevention, on ADAP formularies.News Article updated on 05/15/2023 -
Program Letter: Role of RWHAP in Addressing STIs and Mpox
State AIDS Drug Assistance Programs (ADAPs), which provide medications for people with HIV who lack health coverage. play "a critical role in addressing STIs for people with HIV"News Article updated on 05/24/2023 -
STI Implementation Plan Released
HHS has released an implementation plan on specific actions for entities to take in preventing and treating sexually transmitted infections (STI).News Article updated on 06/13/2023 -
Input Sought on Federal HIV Research Priorities
The NIH Office of AIDS Research (OAR) leads the effort across NIH to establish HIV research priorities and develop the NIH Strategic Plan for HIV and HIV-Related Research.News Article updated on 02/15/2024 -
Recap: Success Stories in the 2023 RWHAP Biennial Report
Way back in September, the document often referred to as the biennial Ryan White report was released by HRSA's HIV/AIDS Bureau (HAB).News Article updated on 11/01/2023 -
HRSA Celebrates the 33rd Anniversary of the Ryan White HIV/AIDS Program
On August 18, we celebrated the 33rd anniversary of the Health Resources and Services Administration’s (HRSA) Ryan White HIV/AIDS Program (RWHAP).News Article updated on 08/25/2023 -
CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children
In November 2023, CDC published new recommendations for hepatitis C testing for perinatally exposed infants and children.News Article updated on 12/19/2023 -
HIV Prevention and Care Improvements Summarized in CDC Surveillance Reports
In the U.S., the number of new HIV cases continue to decline, most people are linked to care within one month of their HIV diagnosis, and 69% reach viral suppression within 6 months of HIV diagnosis.News Article updated on 06/10/2024 -
Ryan White HIV Care and Black/African American People
A significant proportion of African Americans living with HIV/AIDS get care from HRSA's Ryan White HIV/AIDS Program.
Blog updated 03/29/2024
-
Ryan White HIV Care and Women and Girls
From 2010 through 2022, viral suppression increased from 66.3% to 89.9% among female RWHAP clients receiving HIV medical care.Blog updated 04/17/2024
-
Ryan White and World AIDS Day 2022
Learn about World AIDS Day and activities of HRSA's Ryan White HIV/AIDS Program.
Blog updated 11/09/2023
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from the 2017 Ryan White Clinical Conference by Dr. Laura Cheever.
Blog updated 01/13/2023
-
Evidence-Informed Interventions in Four HIV Care Continuum Manuals
Evidence-informed interventions for engaging persons with HIV in care (incarceration/community release; buprenorphine; patient navigation for women of color; peer linkages for women of color).
Blog updated 01/07/2021
-
Long-Acting HIV Treatment Demonstrates Efficacy in People with Challenges Taking Daily Medicine as Prescribed
Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen.News Article updated on 02/28/2024